Manufacturer
Sanofi-Aventis Deutschland GmbH
Contents
Aflibercept
Indication
In combination w/ irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy for adults w/ metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.
Instruction
Administer via IV Infusion/IV Bolus.
Drug interaction
Population pharmacokinetics analysis and inter study comparisons did not reveal any pharmacokinetic drug-drug interaction between aflibercept and the FOLFIRI regimen.
Malaysia
